Management of High-Risk Non-Muscle-Invasive Bladder Cancer.

Area of Science:

• Urology
• Oncology
• Medical Diagnostics

Background:

• High-risk non-muscle-invasive bladder cancer (NMIBC) is biologically diverse, leading to unpredictable recurrence and progression.
• Current risk stratification relies on clinicopathologic features, which often inadequately predict patient outcomes.
• Challenges persist in the diagnosis, risk stratification, and management of this complex disease.

Purpose of the Study:

• To highlight the heterogeneity of high-risk NMIBC.
• To discuss the limitations of current risk stratification methods.
• To explore emerging techniques for improved prognostication.

Main Methods:

• Review of current clinical guidelines and risk stratification factors for NMIBC.
• Discussion of ongoing research in molecular profiling for bladder cancer.
• Evaluation of advanced imaging techniques, specifically multiparametric MRI, in bladder cancer assessment.

Main Results:

• Clinicopathologic features alone provide incomplete prognostication for high-risk NMIBC.
• Molecular profiling and advanced imaging show promise for refining risk prediction.
• Complete transurethral resection (TUR) remains a cornerstone for diagnosis and management.

Conclusions:

• Accurate risk stratification for high-risk NMIBC requires methods beyond traditional clinicopathologic factors.
• Investigational approaches like molecular profiling and multiparametric MRI are crucial for advancing patient care.
• Transurethral resection (TUR) is indispensable for the initial diagnosis and subsequent management of NMIBC.